Last updated: February 16, 2026
What is the current market status of the drug with NDC 00173-0716?
The drug identified by the NDC 00173-0716 is Voxzogo (vosoritide), marketed by BioMarin Pharmaceutical. Approved by the FDA in August 2021, Voxzogo is indicated for the treatment of achondroplasia in pediatric patients aged 5 and older. As of 2023, the drug remains in the early commercialization phase with limited sales data but shows potential market penetration driven by unmet needs in rare pediatric diseases.
How large is the addressable market for Voxzogo?
The primary market is children with achondroplasia, a form of dwarfism. Prevalence estimates indicate approximately 1 in 15,000 to 40,000 live births globally. Based on the World Population data, the estimated global population of children aged 5-17 years with achondroplasia is around 25,000 to 50,000 patients.
Market penetration depends on:
- Approval in additional regions beyond the U.S., including Europe and Japan.
- Physician adoption, influenced by reimbursement policies.
- Competition from other therapies, though few direct competitors exist currently for this indication.
What factors influence the price setting of Voxzogo?
Voxzogo’s pricing involves several considerations:
- Regulatory approval: As an orphan drug, it benefits from some pricing flexibility.
- Manufacturing costs: The drug is a recombinant protein requiring specialized production, adding to costs.
- Reimbursement frameworks: Payer negotiations in different markets impact net price.
- Comparable therapies: No direct approved competitors for achondroplasia-specific treatments currently exist.
In the U.S., recommended retail prices range approximately between $300,000 and $400,000 annually per patient, reflecting high-cost therapy norms for rare diseases.
How does the price compare to similar treatments?
While few direct comparators exist for achondroplasia, other rare disease biologics such as Brineura (cerliponase alfa) (approved for Batten disease) have annual costs exceeding $700,000. The price range for Voxzogo aligns with similar peptide-based orthopedics or growth-disorder therapies.
What revenue projections are possible for Voxzogo?
Assuming:
- Steady growth in sales following increased reimbursement and geographic expansion.
- A conservative adoption rate of 25% of the estimated addressable market within five years.
Revenue estimates position sales between $250 million and $400 million annually after five years, contingent on:
- Approval extension into European markets (expected in 2024).
- Assumption of a 50% gross margin.
- No major discounts or policy barriers limiting sales.
Historically, orphan biologics with similar sales trajectories reached these levels within 5-8 years of launch.
What are the key risks to the market and price projections?
- Delays or failures in obtaining additional regulatory approvals.
- Competitive entries from pipeline therapies or gene editing approaches.
- Reimbursement restrictions or analyses influencing pricing.
- Patient and physician acceptance levels.
Summary of competitive landscape
| Therapy / Company |
Indication |
Approval Status |
Price Range |
Notes |
| Voxzogo (BioMarin) |
Achondroplasia |
FDA approved (2021) |
$300K–$400K/year |
Orphan biologic, early sales |
| Kyowa Kirin – Hemifilgrastim |
N/A |
Not directly competing |
N/A |
Different indication |
| Emerging therapies |
Various |
Early development |
N/A |
Potential future competition |
Key takeaways
- Voxzogo has a niche but significant market, with limited competitors.
- U.S. pricing remains high, consistent with orphan biologics.
- Sales projections depend on geographic expansion, clinical adoption, and reimbursement policies.
- Potential revenue surpasses $250 million annually within five years.
- Market growth hinges on regulatory approvals outside the U.S. and payer strategy.
FAQs
1. What are the main factors affecting Voxzogo’s price?
Regulatory status, manufacturing complexity, reimbursement policies, and comparators influence price levels.
2. How quickly can Voxzogo’s market grow?
Market growth depends on regional approvals, physician adoption, and payer acceptance; it could reach multiple hundreds of millions in annual sales within five years.
3. Are competing therapies in development?
Current competition is minimal. Several pipeline candidates for growth disorders are in early stages but lack commercial approval.
4. How does reimbursement impact pricing?
Reimbursement policies set price ceilings; high-cost therapies often require negotiations and value assessments.
5. What’s the trajectory for Voxzogo’s approval outside the U.S.?
Europe’s CHMP approved the drug in 2022, with commercialization beginning in 2023; Japan and other regions are expected to follow.
Citations:
[1] FDA, "Voxzogo (vosoritide) approval," 2021.
[2] BioMarin Annual Reports, 2022–2023.
[3] World Health Organization, "Prevalence data for achondroplasia," 2022.
[4] Industry analysis reports, 2023.
